MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412537 | Name: Cefroxadine dihydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefroxadine dihydrate is the hydrate from of Cefroxadine (free base), also known as CGP 9000, a cephalosporin antibiotic. It is structurally related to cefalexin, and both drugs share a similar spectrum of activity. It is available in Italy. Cefroxadine (CXD), an orally active cephalosporin antibiotic, has a broad spectrum and a bactericidal action. CXD showed excellent results in the treatment of acute uncomplicated cystitis (AUC).

Chemical Structure

Cefroxadine dihydrate
CAS#95615-72-8 (dihydrate)

Theoretical Analysis

MedKoo Cat#: 412537

Name: Cefroxadine dihydrate

CAS#: 95615-72-8 (dihydrate)

Chemical Formula: C16H23N3O7S

Exact Mass: 401.1257

Molecular Weight: 401.43

Elemental Analysis: C, 47.87; H, 5.78; N, 10.47; O, 27.90; S, 7.99

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
51762-05-1 (free) 95615-72-8 (dihydrate)
Synonym
Cefroxadine dihydrate; CGP-9000 dihydrate; UNII-439L36E61V
IUPAC/Chemical Name
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methoxy-8-oxo-, dihydrate, (6R-(6-alpha,7-beta(R*)))-
InChi Key
WDYHZZPITKKPTD-HCCBYIMHSA-N
InChi Code
InChI=1S/C16H19N3O5S.2H2O/c1-24-9-7-25-15-11(14(21)19(15)12(9)16(22)23)18-13(20)10(17)8-5-3-2-4-6-8;;/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23);2*1H2/t10?,11-,15-;;/m1../s1
SMILES Code
O=C(C(N12)=C(OC)CS[C@]2([H])[C@H](NC(C(N)C3=CCC=CC3)=O)C1=O)O.[H]O[H].[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 401.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kang YS, Lee SY, Kim NH, Choi HM, Park JS, Kim W, Lee HJ. A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean. J Pharm Biomed Anal. 2006 Feb 13;40(2):369-74. Epub 2005 Aug 30. PubMed PMID: 16137854. 2: Kitagawa S, Takeda J, Sato S. pH-dependent inhibitory effects of angiotensin-converting enzyme inhibitors on cefroxadine uptake by rabbit small intestinal brush-border membrane vesicles and their relationship with hydrophobicity and the ratio of zwitterionic species. Biol Pharm Bull. 1999 Jul;22(7):721-4. PubMed PMID: 10443470. 3: Kitagawa S, Takeda J, Kaseda Y, Sato S. Inhibitory effects of angiotensin-converting enzyme inhibitor on cefroxadine uptake by rabbit small intestinal brush border membrane vesicles. Biol Pharm Bull. 1997 Apr;20(4):449-51. PubMed PMID: 9145229. 4: Kitagawa S, Sugaya Y. Characteristics of uptake of cefroxadine by rabbit small intestinal brush border membrane vesicles. Biol Pharm Bull. 1996 Feb;19(2):268-73. PubMed PMID: 8850320. 5: Beyssac E, Ritschel WA, Aiache JM, Haberer JP. Comparison of continuous, constant rate enteral tube feeding in supine patients to bolus food intake in ambulatory, healthy subjects regarding bioavailability of perorally administered cefroxadine. Methods Find Exp Clin Pharmacol. 1991 Nov;13(9):637-42. PubMed PMID: 1787771. 6: Beyssac E, Ritschel WA, Aiache JM, Haberer JP. Peroral absorption of cefroxadine in patients within the first day after severe trauma: comparison to cefroxadine pharmacokinetics in fasted, healthy volunteers. Methods Find Exp Clin Pharmacol. 1991 Oct;13(8):565-72. PubMed PMID: 1956212. 7: Mendizabal MV, Idoate I, Jordan J, Larralde J. Effects of cefroxadine on L-leucine absorption in rat jejunum. Arch Int Physiol Biochim Biophys. 1991 Jun;99(3):247-50. PubMed PMID: 1717060. 8: Cadórniga R, Molina IT, Pastoriza P, Negro S, Evora CM, Gutierrez JA. Pharmacokinetics of cefroxadine after infusion to healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1990 Oct;28(10):435-9. PubMed PMID: 2258253. 9: Shibl AM, Durgham SM. In-vitro evaluation of a new oral cephalosporin, cefroxadine (CGP 9000). J Chemother. 1990 Feb;2(1):8-10. PubMed PMID: 2332786. 10: Scaglione F, Cattaneo G, Bianchi MM, Verdecchia P, Maresca V, Bichisao E, Fraschini F. Cefroxadine in the treatment of children affected by respiratory and ENT diseases. A multicentre study involving 1072 in-patients. Drugs Exp Clin Res. 1989;15(2):71-6. PubMed PMID: 2737082. 11: Fraschini F, Scaglione F, Vago F, Bichisao E, Borghi C, Montanari M. Correlation between plasma and tonsillar levels of cefroxadine. Chemotherapy. 1988;34(1):8-12. PubMed PMID: 3349862. 12: Kumon H, Ohmori H. [A clinical study on cefroxadine in the treatment and recurrence of acute uncomplicated cystitis]. Jpn J Antibiot. 1987 Apr;40(4):703-10. Japanese. PubMed PMID: 3613088. 13: Nieto MJ, González JL, Dominguez-Gil A, Lanao JM. Determination of the thermodynamic ionization constants of cefroxadine. J Pharm Sci. 1987 Mar;76(3):228-30. PubMed PMID: 3585739. 14: Matsunaga T, Ogino H, Asai H, Shiraishi T, Kawamura S, Onishi S, Ueda R, Kobayashi K, Itoh Y, Sakamoto Y, et al. [A parallel comparative double blind study of cefixime with cefroxadine in the treatment of acute lacunar tonsillitis]. Jpn J Antibiot. 1987 Jan;40(1):25-54. Japanese. PubMed PMID: 3295323. 15: Iwata S, Yokota T, Kusumoto Y, Shiro H, Sato Y, Akita H, Nanri S, Oikawa T, Kusano S, Sunakawa K, et al. [Influence of cefroxadine dry syrup on intestinal bacterial flora]. Jpn J Antibiot. 1986 Aug;39(8):1967-74. Japanese. PubMed PMID: 3540337. 16: Salvato A, Calderini A, Zambruno E. [Clinical use of Cefroxadine in oral medicine]. Dent Cadmos. 1985 Sep 30;53(14):115-6, 119-20, 123-4. Italian. PubMed PMID: 3869543. 17: Hara J, Tanaka Y, Harino S, Deguchi K. [Study on the transfer of cefroxadine to human tears]. Jpn J Antibiot. 1985 Feb;38(2):230-4. Japanese. PubMed PMID: 4009946. 18: Hess J, Gammelgaard P, Holst B, Rasmussen F, Thomsen VF. A randomized double-blind investigation of cefroxadine (CGP 9000) versus cephalexin in urinary tract infection. Infection. 1984 Jul-Aug;12(4):270-3. PubMed PMID: 6436182. 19: Aikawa T, Noguchi S, Fujimoto N, Mizushima H, Shibata N, Tomita N, Horii A. [Clinical effect of cefroxadine on surgical infections]. Jpn J Antibiot. 1983 Sep;36(9):2521-8. Japanese. PubMed PMID: 6686263. 20: Ooishi M, Nagai S, Nishizuka K, Tanaka R, Takagi K, Hara J, Tanaka Y, Ichihashi K, Hirose Y, Akashi N, et al. [Clinical evaluation of cefroxadine in bacterial infections of the eye]. Jpn J Antibiot. 1983 Sep;36(9):2635-64. Japanese. PubMed PMID: 6655872.